Applicants: Carlos Cordon-Cardo et al.

Serial No.: 10/009,861 Filed: December 10, 2001

Page 3

## In the claims:

Please replace the claims with the listing of claims below.

## 1. - 18. (cancelled)

19. (currently amended) A method of for treating prostate cancer in a subject, wherein the prostate cancer is characterized by overexpression of Her-2/neu protein, comprising administering to the subject [[a]] therapeutically effective amount amounts of anti-Her-2/neu (i) a humanized monoclonal antibody which specifically binds to an extracellular domain of the Her-2/neu protein and (ii) an antitumor chemotherapeutic agent, so as to thereby treat prostate cancer in the subject.

## 20. - 27. (cancelled)

28. (currently amended) The method of claim [[27]] 19, wherein the antitumor chemotherapeutic agent is selected from the group consisting of paclitaxel, doxorubicin, cis-platin, cyclophosphamide, etoposide, vinorelbine, vinblastin, tamoxifen, colchinin, and 2-methoxyestradiol.

## 29. (cancelled)

30. (previously presented) The method of claim 19, wherein the prostate cancer is androgen-independent.